{"title":"From early methods for DNA diagnostics to genomes and epigenomes at high resolution during four decades - a personal perspective.","authors":"Ann-Christine Syvänen","doi":"10.48101/ujms.v129.11134","DOIUrl":null,"url":null,"abstract":"<p><p>In the 1980s, my research career begun with microbial DNA diagnostics at Orion Pharmaceutica in Helsinki, Finland, where I was part of an innovative team that developed novel methods based on the polymerase chain reaction (PCR) and the biotin-avidin interaction. One of our key achievements during this time was the invention of the solid-phase minisequencing method for genotyping single nucleotide polymorphisms (SNPs). In the 1990s, I shifted focus to human genetics, investigating mutations of the 'Finnish disease heritage'. During this period, I also developed quantitative methods using PCR and minisequencing of mitochondrial mutations and for forensic analyses. In the late 1990s and early 2000s, microarray-based SNP genotyping became a major topic for my research, first in Helsinki and later with my research group at Uppsala University in Sweden. By the mid-2000s, I began collaborating with leading clinicians on genetics of autoimmune disease, specifically systemic lupus erythematosus and later worked on the classification and clinical outcome of pediatric acute lymphoblastic leukemia, when large-scale genomics and epigenomics emerged. These collaborations, which focused on integrating genomics into clinical practice, lasted almost two decades until I retired from research in 2022. In parallel with my research activities, I led the SNP/DNA Technology Platform in the Wallenberg Consortium North program from 2001 to 2006. I continued as Director of the SNP&SEQ Technology Platform, which expanded rapidly during the 2010s, and became part of Science for Life Laboratory in 2013. Today (in 2024), the SNP&SEQ Technology Platform is one of the largest units of the Swedish National Genomics Infrastructure hosted by SciLifeLab. The present article provides a personal perspective on nearly four decades of research, highlighting projects and methods I found particularly exciting or important.</p>","PeriodicalId":23458,"journal":{"name":"Upsala journal of medical sciences","volume":"129 ","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11650520/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Upsala journal of medical sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.48101/ujms.v129.11134","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
In the 1980s, my research career begun with microbial DNA diagnostics at Orion Pharmaceutica in Helsinki, Finland, where I was part of an innovative team that developed novel methods based on the polymerase chain reaction (PCR) and the biotin-avidin interaction. One of our key achievements during this time was the invention of the solid-phase minisequencing method for genotyping single nucleotide polymorphisms (SNPs). In the 1990s, I shifted focus to human genetics, investigating mutations of the 'Finnish disease heritage'. During this period, I also developed quantitative methods using PCR and minisequencing of mitochondrial mutations and for forensic analyses. In the late 1990s and early 2000s, microarray-based SNP genotyping became a major topic for my research, first in Helsinki and later with my research group at Uppsala University in Sweden. By the mid-2000s, I began collaborating with leading clinicians on genetics of autoimmune disease, specifically systemic lupus erythematosus and later worked on the classification and clinical outcome of pediatric acute lymphoblastic leukemia, when large-scale genomics and epigenomics emerged. These collaborations, which focused on integrating genomics into clinical practice, lasted almost two decades until I retired from research in 2022. In parallel with my research activities, I led the SNP/DNA Technology Platform in the Wallenberg Consortium North program from 2001 to 2006. I continued as Director of the SNP&SEQ Technology Platform, which expanded rapidly during the 2010s, and became part of Science for Life Laboratory in 2013. Today (in 2024), the SNP&SEQ Technology Platform is one of the largest units of the Swedish National Genomics Infrastructure hosted by SciLifeLab. The present article provides a personal perspective on nearly four decades of research, highlighting projects and methods I found particularly exciting or important.
在20世纪80年代,我的研究生涯开始于芬兰赫尔辛基的Orion制药公司的微生物DNA诊断,在那里我是一个创新团队的一员,该团队开发了基于聚合酶链反应(PCR)和生物素-亲和素相互作用的新方法。在此期间,我们的主要成就之一是发明了用于单核苷酸多态性(snp)基因分型的固相微测序方法。在20世纪90年代,我将注意力转移到人类遗传学上,研究“芬兰疾病遗传”的突变。在此期间,我还开发了定量方法,使用PCR和线粒体突变的微测序以及法医分析。在20世纪90年代末和21世纪初,基于微阵列的SNP基因分型成为我研究的一个主要课题,首先是在赫尔辛基,后来是在瑞典乌普萨拉大学的研究小组。到2000年代中期,我开始与领先的临床医生合作研究自身免疫性疾病的遗传学,特别是系统性红斑狼疮。后来,当大规模基因组学和表观基因组学出现时,我开始研究儿科急性淋巴细胞白血病的分类和临床结果。这些合作的重点是将基因组学整合到临床实践中,持续了近20年,直到我于2022年从研究中退休。与我的研究活动并行,我在2001年至2006年期间领导了瓦伦堡财团北方项目的SNP/DNA技术平台。我继续担任SNP&SEQ技术平台的总监,该平台在2010年代迅速扩张,并于2013年成为Science for Life Laboratory的一部分。今天(2024年),SNP&SEQ技术平台是由sciilifelab托管的瑞典国家基因组基础设施中最大的单位之一。本文提供了近四十年研究的个人观点,重点介绍了我认为特别令人兴奋或重要的项目和方法。
期刊介绍:
Upsala Journal of Medical Sciences is published for the Upsala Medical Society. It has been published since 1865 and is one of the oldest medical journals in Sweden.
The journal publishes clinical and experimental original works in the medical field. Although focusing on regional issues, the journal always welcomes contributions from outside Sweden.
Specially extended issues are published occasionally, dealing with special topics, congress proceedings and academic dissertations.